Levodopa/Benserazid Devatis (Benserazide, Levodopa)

Levodopa/Benserazide, the active ingredient in Levodopa/Benserazid Devatis, is an Antiparkinson agent presented as an oral dosage form for oral use. It treats Parkinson's disease by compensating for dopaminergic deficiency in adult patients. GNH USA supplies Levodopa/Benserazid Devatis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Benserazide is used within the antiparkinson therapeutic pathway to restore dopamine activity in the central nervous system. - Parkinson's disease (early stage): reduces rigidity, tremor and bradykinesia. - Parkinson's disease (advanced with motor fluctuations): smooths out on‑off periods and improves overall motor function. - Parkinsonian syndrome secondary to drug‑induced or vascular causes: alleviates dopaminergic deficiency and supports motor control.

Levodopa/Benserazide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension leading to syncope - Cardiac arrhythmias - Neuroleptic malignant‑like syndrome - Severe skin reactions (e.g., Stevens‑Johnson syndrome).

Levodopa/Benserazide requires careful monitoring to minimise risks and optimise benefit. - Blood pressure monitoring: watch for orthostatic hypotension, especially after dose initiation. - Dyskinesia assessment: evaluate for involuntary movements during therapy adjustments. - Discontinuation: avoid abrupt cessation to prevent withdrawal syndrome. - Hepatic impairment: use with caution, as metabolism may be altered. - Pregnancy and lactation: safety unknown; weigh potential benefits against risks. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Levodopa/Benserazide can interact with several drug classes, requiring dose adjustments or avoidance.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - High‑dose anticholinergics: may mask motor symptoms. - Iron or calcium supplements taken concurrently: reduce levodopa absorption.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors (e.g., selegiline): may enhance dopaminergic effects. - Antihypertensive agents: additive blood‑pressure lowering effect.